Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for maintenance treatment of extensive-stage small-cell lung cancer after chemotherapy.
Status In progress
Process STA 2018
ID number 1264

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
17 October 2018 - 14 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance